首页> 外文期刊>International Journal of Nanomedicine >Metoclopramide nanoparticles modulate immune response in a diabetic rat model: association with regulatory T cells and proinflammatory cytokines
【24h】

Metoclopramide nanoparticles modulate immune response in a diabetic rat model: association with regulatory T cells and proinflammatory cytokines

机译:甲氧氯普胺纳米颗粒调节糖尿病大鼠模型的免疫反应:与调节性T细胞和促炎细胞因子的关联

获取原文
           

摘要

Background: The inflammatory basis of diabetes mellitus directed the researchers’ attention to the immune system for better management and prevention of complications. Metoclopramide (MCA; the only US Food and Drug Administration-approved for gastroparesis) has the ability to restore immune function through increasing prolactin secretion. This study aimed to test the effect of BSA/MCA nanoparticles (NPs) on modulating immune response. Methods: BSA/MCA NPs were fabricated by desolvation and evaluated in?vitro via measuring loading efficiency, particle size, and surface charge. The selected formula was further evaluated via differential scanning calorimetry and release behavior. Then, NPs were injected into rats (25 mg MCA/kg/week) for 3 weeks to be evaluated histopathologically and immunologically via measuring proinflammatory cytokines, such as IL1β, IL6, and TNFα, in addition to measuring regulatory T-cell frequency. Results: MCA was successfully loaded on BSA, achieving high encapsulation efficiency reaching 63±2%, particles size of 120–130 nm with good polydispersity, and a negative surface charge indicating that entire positively charged drug was encapsulated inside NPs. Differential scanning calorimetry thermography of selected NPs showed an obvious interaction between components and cross-linking of BSA molecules using glutaraldehyde, resulting in sustained release of MCA (around 50% within 3 days). MCA NPs significantly restored the immune response via decreasing proinflammatory cytokines and increasing regulatory T-cell frequency when compared to control and free MCA (drug not loaded in NPs)-treated groups. Histopathological examination of this MCA NPs-treated group did not show the characteristic lesions of diabetes, and apoptosis nearly disappeared. Conclusion: BSA/MCA NPs could be considered a new modality for treatment of gastroparesis, in addition to management of diabetes itself and preventing its complications via an MCA-immunomodulatory effect.
机译:背景:糖尿病的炎症基础促使研究人员将注意力转移到免疫系统上,以更好地管理和预防并发症。甲氧氯普胺(MCA;美国唯一的胃轻瘫批准食品和药物管理局)具有通过增加催乳激素分泌来恢复免疫功能的能力。这项研究旨在测试BSA / MCA纳米颗粒(NP)对调节免疫反应的影响。方法:通过去溶剂化制备BSA / MCA NP,并通过测量负载效率,粒径和表面电荷进行体外评估。通过差示扫描量热法和释放行为进一步评估所选配方。然后,将NPs注射到大鼠中(25 mg MCA / kg /周),持续3周,通过测量促炎细胞因子(例如IL1β,IL6和TNFα),以及测量调节性T细胞频率,对其进行组织病理学和免疫学评估。结果:MCA成功装载到BSA上,达到了63±2%的高包封率,粒径为120–130 nm,具有良好的多分散性,并且带负电荷的表面表明整个带正电荷的药物被囊封在NP内。所选NP的差示扫描量热法热成像显示,戊二醛与BSA分子的交联之间存在明显的成分相互作用,并导致MCA的持续释放(3天内约占50%)。与对照组和游离MCA(未装载在NPs中的药物)治疗组相比,MCA NPs通过减少促炎性细胞因子和增加调节性T细胞频率来显着恢复免疫反应。该MCA NPs治疗组的组织病理学检查未显示糖尿病的特征性病变,并且凋亡几乎消失。结论:BSA / MCA NPs除了可以治疗糖尿病并通过MCA免疫调节作用预防并发症外,还可被视为治疗胃轻瘫的一种新方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号